Ciba Consumer Pharmaceuticals
Obtains license to Boehringer Ingelheim's Dulcolax laxative and acquires Boehringer's Nostril and Nostrilla nasal decongestants. Ciba Consumer already markets Fiberall, a bulk laxative, and describes stimulant laxative Dulcolax as "a leader in the laxative market." Ciba currently has two OTC decongestants on the market, Otrivin and Privine. Terms of the deal were not disclosed.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth